Business Standard

Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%

Technically, the Nifty Pharma index needs to immediate hurdle at 13,500, for further upside to 14,250.

Illustration: Binay Sinha
Web Exclusive Premium

Rise in Covid csaes may steer uncertainty in global stock markets.

Avdhut Bagkar Mumbai
Stock markets across the globe this traded on a jittery note amid reports of fresh spike in COVID-19 cases across China, and also cities in the US, Europe and Japan. The Indian markets slipped over 2 per cent in the previous two trading sessions and have plunged 4.7 per cent from the all-time high recorded at the start of this December. 

Even as the US benchmarks, Dow Jones and Nasdaq trade in green for the current week, both the indices were 4 per cent lower from their recent 3-week highs. Similarly, FTSE in UK, DAX in Germany and CAX in

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Dec 23 2022 | 12:18 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com